Loading clinical trials...
Loading clinical trials...
The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bagcilar Training and Research Hospital
NCT04565665 · COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, and more
NCT07504731 · Acute Respiratory Distress Syndrome (ARDS)
NCT06703073 · Acute Respiratory Distress Syndrome (ARDS), ARDS, and more
NCT07123961 · Acute Respiratory Distress Syndrome (ARDS), Ventilator Management, and more
NCT07450846 · Acute Respiratory Distress Syndrome, Right Heart Failure
Istanbul Bagcılar Training and Research Hospital
Istanbul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions